SciELO - Scientific Electronic Library Online

 
vol.26 issue3Acute Respiratory Failure: Existential Questions in Internal Medicine Fellowship author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Medicina Interna

Print version ISSN 0872-671X

Abstract

BRILHANTE, Dialina et al. Iron Metabolism, Biomarkers, Iron Overload and Chelation: Consensus in Myelodysplastic Syndromes. Medicina Interna [online]. 2019, vol.26, n.3, pp.223-231. ISSN 0872-671X.  https://doi.org/10.24950/rspmi/Revisao/225/18/3/2019.

Myelodysplastic syndromes (MDS) are a diverse group of myeloid neoplasias, characterized by cytopenias stemming from ineffective hematopoiesis and by an increased risk of progression to acute myeloid leukemia. They affect 5/100 000 people per year in Portugal, among which more than 60% will become transfusion-dependent during the course of the disease. Cytopenias may lead to significant morbidity and their correct management is the key to maintain these patients’ quality of life. This document gathers the result of the debate promoted by the Anemia Working Group Portugal with experts on the management of patients with lower risk MDS, addressing the medium- and long-term effects of recurrent transfusion and iron overload. For the diagnosis of MDS, the group recommends the use of World Health Organization classification published in 2016. The International Prognosis Scoring System score is still the reference score to define both the prognosis and the therapeutic strategy. Support therapy is a fundamental cornerstone in the management of MDS patients at any stage of the disease, and includes antibiotics, transfusion of erythrocytes and platelets, hematopoietic growth factors, antifibrinolytic agents and chelators. Chelation therapy should be considered in patients transfused with = 20 units of erythrocytes or with serum ferritin = 1000 ng/mL. Patients who are candidates to chelation should be submitted to periodic magnetic resonance imaging to the liver and the pancreas. Therapeutic options should take into account the individual characteristics of the disease for every patient and preserve the quality of live, in accordance with international guidelines.

Keywords : Blood Transfusion; Chelation Therapy; Consensus; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License